NeuroMetrix (NASDAQ:NURO) Coverage Initiated by Analysts at StockNews.com

StockNews.com initiated coverage on shares of NeuroMetrix (NASDAQ:NURO) in a report published on Sunday morning. The firm issued a sell rating on the medical device company’s stock.

NeuroMetrix Price Performance

Shares of NASDAQ NURO opened at $4.38 on Friday. The business has a 50-day moving average of $4.08 and a 200-day moving average of $3.96. The stock has a market capitalization of $8.93 million, a price-to-earnings ratio of -0.95 and a beta of 2.18. NeuroMetrix has a fifty-two week low of $2.66 and a fifty-two week high of $4.73.

Hedge Funds Weigh In On NeuroMetrix

An institutional investor recently bought a new position in NeuroMetrix stock. GTS Securities LLC bought a new stake in NeuroMetrix, Inc. (NASDAQ:NURO) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 22,759 shares of the medical device company’s stock, valued at approximately $90,000. GTS Securities LLC owned 1.12% of NeuroMetrix as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 19.40% of the company’s stock.

NeuroMetrix Company Profile

NeuroMetrix, Inc, a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use.